Table 3.
The first and second-line chemotherapy regimen of control and study group
| Patient characteristics | First-line | Second-line | ||
|---|---|---|---|---|
| Control | Study | Control | Study | |
| Number | 446 | 60 | 163 | 22 |
| Oxaliplatin based | 357 | 29 | 41 | 12 |
| Irinotecan based | 75 | 31 | 113 | 10 |
| Other chemotherapy | 14 | 0 | 9 | 0 |
Study group: the group of patients receiving bevacizumab; oxaliplatin-based: FOLFOX, XELOX; irinotecan-based: FOLFIRI, IFL, CPT-11+xeloda.
Control group: the group of patients not receiving bevacizumab; oxaliplatin-based: FOLFOX, XELOX, oxaliplatin+S-1; irinotecan-based: FOLFIRI, CPT-11+S-1